Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference
February 04 2019 - 8:30AM
Business Wire
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty
pharmaceutical company focused on identifying and developing drugs
that address diseases with high unmet medical need, today announced
that management is scheduled to present and conduct one-on-one
meetings at the 2019 BIO CEO & Investor Conference to be held
in New York, NY on February 11th and 12th. Anthony DiTonno, Chief
Executive Officer, is scheduled to present on Tuesday, February
12th at 2:15 p.m. Eastern Time.
About Tenax Therapeutics
Tenax Therapeutics, Inc., is a specialty pharmaceutical company
focused on identifying and developing drugs that address diseases
with high unmet medical need. The Company has a world-class
scientific team including recognized global experts in pulmonary
hypertension. The Company owns the North American rights to develop
and commercialize levosimendan and has initiated a Phase 2 clinical
trial for the use of levosimendan in the treatment of Pulmonary
Hypertension associated with Heart Failure and preserved Ejection
Fraction (PH-HFpEF). For more information, visit
www.tenaxthera.com.
About Levosimendan
Levosimendan is a calcium sensitizer that works through a unique
triple mechanism of action. It initially was developed for
intravenous use in hospitalized patients with acutely decompensated
heart failure. It was discovered and developed by Orion Pharma,
Orion Corporation of Espoo Finland, and is currently approved in
over 60 countries for this indication and not available in the
United States. Tenax Therapeutics acquired the North American
rights to develop and commercialize levosimendan from Phyxius
Pharma, Inc.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by
the Company that involve risks and uncertainties and reflect the
Company’s judgment as of the date of this release. The
forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to matters beyond the
Company’s control that could lead to delays in the clinical study,
new product introductions and customer acceptance of these new
products; matters beyond the Company’s control that could impact
the Company’s continued compliance with Nasdaq listing
requirements; the impact of management changes on the Company’s
business and unanticipated charges, costs and expenditures not
currently contemplated that may occur as a result of management
changes; and other risks and uncertainties as described in the
Company’s filings with the Securities and Exchange Commission,
including in its annual report on Form 10-K filed on April 2, 2018,
its quarterly report on Form 10-Q filed on November 15, 2018 as
well as its other filings with the SEC. The Company disclaims any
intent or obligation to update these forward-looking statements
beyond the date of this release. Statements in this press release
regarding management’s future expectations, beliefs, goals, plans
or prospects constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of
1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190204005008/en/
Investor Contact:ICRStephanie Carrington,
646-277-1282Stephanie.carrington@icrinc.com
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Sep 2023 to Sep 2024